Synlogic, Inc. (NASDAQ:SYBX – Get Free Report) passed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $1.40 and traded as low as $1.38. Synlogic shares last traded at $1.39, with a volume of 2,106 shares changing hands.
Synlogic Price Performance
The company has a market cap of $16.20 million, a P/E ratio of -0.33 and a beta of 0.81. The company has a fifty day simple moving average of $1.40 and a 200-day simple moving average of $1.43.
Synlogic Company Profile
Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.
Read More
- Five stocks we like better than Synlogic
- Differences Between Momentum Investing and Long Term Investing
- Will Alibaba’s $53B AI Bet Be the Key to Tech Supremacy?
- How to Use the MarketBeat Stock Screener
- Builders FirstSource Is Laying the Foundation for a Rebound
- The 3 Best Retail Stocks to Shop for in August
- Domino’s Pizza Delivers a Buying Opportunity
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.